Compare NBIX & WMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | WMG |
|---|---|---|
| Founded | 1992 | 1929 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 14.4B |
| IPO Year | 1996 | 2005 |
| Metric | NBIX | WMG |
|---|---|---|
| Price | $130.52 | $27.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 13 |
| Target Price | ★ $180.91 | $36.38 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.72% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 4.67 | N/A |
| Revenue | $161,626,000.00 | ★ $4,463,000,000.00 |
| Revenue This Year | $24.73 | $7.20 |
| Revenue Next Year | $13.14 | $5.99 |
| P/E Ratio | $27.99 | ★ N/A |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $107.96 | $23.34 |
| 52 Week High | $160.18 | $34.63 |
| Indicator | NBIX | WMG |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 48.35 |
| Support Level | $124.62 | $26.59 |
| Resistance Level | $135.88 | $27.90 |
| Average True Range (ATR) | 3.58 | 0.77 |
| MACD | -0.12 | -0.11 |
| Stochastic Oscillator | 59.98 | 22.76 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Warner Music is the third-largest of the three major record companies. Recorded music accounts for most of the firm's revenue, with the segment housing notable record labels including Atlantic Records, Warner Records, Elektra Records. Some of the most successful current artists signed to record deals with Warner include Ed Sheeran, Bruno Mars, Cardi B, and Dua Lipa. Warner's remaining revenue comes from its publishing business, where Warner Chappell represents more than 180,000 songwriters and composers, some of whom are also Warner recording artists but many of whom are not recording artists or are attached to other labels. Warner Chappell controls more than 1 million musical compositions. Access Industries controls 98% of Warner's voting rights, while holding a 72% economic interest.